BCOP Updates 2026: Bundle

Type: Bundle•Format: On-demand

The 2026 BCOP Updates Bundle offers 9.0 BCOP CE hours and ACPE CE hours.

BCOP Updates modules are on-demand and allow you to review and complete at your convenience for up to one year following the release of the education.

The modules may be completed in any order. Each contains an ACPE Pre-Test, narrated slide deck, an ACPE and BCOP Post-Test, and a Course Evaluation. In order to claim BCOP credit, you must pass the BCOP Post-Test with 75% or higher.

This bundle contains the following modules:

  • Module 1: Beyond Steroids: Updates in Chronic Graft-Versus-Host Disease
  • Module 2: How Low Should We Go? Incorporating Updates in HER2-Targeted Treatments for Metastatic Breast Cancer into Clinical Practice
  • Module 3: Myth Busters: Hormone Replacement Therapy and Supplements in Breast and Gynecological Cancers
  • Module 4: Outpatient Administration of Desensitization Protocols, High-Dose Methotrexate, and Other Complex Therapies
  • Module 5: Stepping-Up Your Game: Outpatient Myeloma Bispecifics
  • Module 6: Supporting the War Against Cancer: Fighting Fatigue and Combating Cachexia
  • Module 7: Updates in Cancer Pain Management
  • Module 8: Updates in Lung Cancer
  • Module 9: Don't Break My Heart: Cardio-monitoring and Prevention of Treatment-induced Cardiovascular Toxicity in Oncology

Get the bundle

Course Learning Objectives

Author: C. Brooke Adams, PharmD, BCOP

UAN#: 0465-0000-26-081-H01-P

Learning Objectives

  1. Describe the role and mechanisms of action of ibrutinib, ruxolitinib, belumosudil, and axatilimab in the treatment of steroid refractory chronic graft-versus-host disease (SR GVHD)
  2. Summarize adverse events, organ system response rates, and drug interactions for ibrutinib, ruxolitinib, belumosudil, and axatilimab
  3. Design individualized treatment plans for SR GVHD patients using clinical trial data and patient specific factors
  4. Discuss sequencing principles and the future direction of these therapies for the treatment of cGHVD

Author: Julia L. Ziegengeist, PharmD, BCOP

UAN#: 0465-0000-26-082-H01-P

Learning Objectives

  1. Review HER2 (human epidermal growth factor receptor 2) testing and associated HER2-targeted treatment options
  2. Identify patients who are candidates for treatment with HER2-targeted agents
  3. Analyze literature regarding treatment of HER2+, HER2-low, and HER2-ultralow metastatic breast cancer
  4. Recommend appropriate HER2-targeted treatment strategies for patients diagnosed with metastatic breast cancer

Author: Miranda Benfield, PharmD, BCOP

UAN#: 0465-0000-26-083-H01-P

Learning Objectives

  1. Analyze current evidence and clinical controversies surrounding hormone replacement therapy (HRT) in patients with breast and gynecologic cancers
  2. Discuss commonly used non-hormonal medications and supplements among patients with breast and gynecologic cancers and evaluate their potential risks, benefits, and drug interactions
  3. Evaluate the appropriateness of hormone replacement therapy (HRT) in a postmenopausal patient by integrating clinical trial evidence, patient-specific risk factors, and guideline recommendations to formulate an evidence-based treatment plan
  4. Develop individualized management strategies for menopausal symptoms in patients with breast or gynecologic cancer by comparing hormonal and non-hormonal options and incorporating patient-specific factors

Author: Emily Rux, PharmD, BCOP

UAN#: 0465-0000-26-084-H99-P

Learning Objectives

  1. Explain the rationale for transitioning traditionally inpatient chemotherapy regimens, such as desensitization protocols or high-dose methotrexate, to the outpatient setting
  2. Describe patient selection criteria and monitoring parameters that ensure safe and effective outpatient delivery of complex chemotherapy regimens
  3. Discuss common toxicities, rescue strategies, and escalation protocols to manage complications during outpatient administration of complex chemotherapy regimens
  4. Evaluate clinical, operational, and financial outcomes of administering classically inpatient chemotherapy regimens in the outpatient setting

Author: Shahrier Hossain, PharmD, BCOP

UAN#: 0465-0000-26-085-H01-P

Learning Objectives

  1. Outline an outpatient step-up dosing program for multiple myeloma bispecific antibodies
  2. Explain the management of cytokine release syndrome as an outpatient ambulatory care center
  3. Identify key stakeholders in their institution to develop an outpatient step-up dosing program
  4. Select patients appropriate for outpatient step-up dosing

Author: Amber B. Clemmons, PharmD, BCOP, FHOPA

UAN#: 0465-0000-26-086-H01-P

Learning Objectives

  1. Describe cancer-related fatigue and cachexia and their impact on patients with cancer
  2. Examine recent literature evaluating the various interventions for the treatment of cancer-related fatigue and cachexia
  3. Evaluate pharmacologic interventions for fatigue and cachexia in patients with cancer
  4. Summarize guideline recommendations for the diagnosis and management of cancer-related fatigue and cachexia

Author: Wai Tak Vince Sung, PharmD, MBA, BCOP, BCSCP

UAN#: 0465-0000-26-087-H08-P

Learning Objectives

  1. Review the current landscape and pathophysiology of cancer-related pain
  2. Outline current pharmacologic options in managing cancer pain
  3. Examine non-pharmacologic strategies in cancer pain management
  4. Explore novel and emerging therapies for the treatment of cancer pain

Author: Ming-Hei Tai, PharmD, BCOP

UAN#: 0465-0000-26-088-H01-P

Learning Objectives

  1. Summarize the mechanisms of actions of novel therapies in lung cancer
  2. Discuss the role of novel therapies in lung cancer
  3. Define the side effects of novel therapies in lung cancer
  4. Describe possible adverse event management strategies for novel agents

Authors: Rodney Hunter, PharmD, BCOP, and Jennifer McDonald, PharmD, BCOP

UAN#: 0465-0000-26-089-H01-P

Learning Objectives

  1. Explain the mechanism of cardiotoxicity associated with anthracyclines, HER-2 targeted inhibitors, and immune checkpoint inhibitors
  2. Evaluate the benefits of left ventricular ejection fraction (LVEF) and lab monitoring assessment tools for prevention of cardiotoxicity during treatment
  3. Discuss the limitations of the clinical use of beta blockers and ACE inhibitors for prevention of cardiovascular toxicity
  4. Compare and contrast interventions for prevention of anthracycline, HER-2 targeted inhibitor, and immune checkpoint inhibitor induced cardiovascular toxicity

Knowledge Course for Pharmacist

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.